November 2018        
The MPN Community Connection
Educating and Advocating on behalf of those affected by myelofibrosis,
polycythemia vera, and essential thrombocythemia  
2017 Events
Friday
November 10 
Washington, DC 
 
S peakers
Two New Lab Concepts: Future Clinical Trials
Dr. Raajit Rampal

MPN Scientific Journey: 2005-2017
Dr. Srdan Verstovsek

MPN Case Studies
Dr. Wendy Bernstein 

Living & Surviving with an MPN
Dr. Anas Al-Janadi

Amy Niles, PAN Foundation
Flyer  

2018 Events
 
Saturday
February 24, 2018  
San Antonio, Texas

Speakers
Dr. Ruben Mesa
Dr. Jason Gotlib
Dr. Robyn Scherber
Dr. Laura Michaelis
Dr. Willis Navarro
Dr. Jeanne Palmer

March
San Mateo, CA

April
Nashville, TN

May 31
Cleveland, OH

June
Pittsburgh, PA  
Living in Paradox

by Marina S. Peed

November : 
You Are Not Alone

Visit our blog
Coming in December's 
newsletter 
 
ASH Updates

Highlights from Washington DC Patient/Caregiver Program  
Upcoming Support Group Meetings 
November 4
New Mexico

November 14
Idaho

November 16
Pennsylvania

November 18
Tokyo, Japan

Tennessee Support Group Forming contact us for details
   

Staying Healthy with the Help of Apps
  
Mobile phone apps are quickly becoming a valuable resource for patients and caregivers as they navigate the journey of living with an MPN.  Below are a few apps that reviewers have found helpful for patients with chronic illnesses
(click on the image 
to learn more):

Ask the Nutritionist

Dana-Farber Cancer Institute created this app to help you find recipes for staying healthy, getting you through treatment, and living and eating healthy.

Loving Meditations to Bring Calm to Cancer
 


Medisafe Pill Tracker

MediSafe is intended for patients who are on multiple medications for chronic diseases and who have a hard time complying with their prescription medications. 
Follow Us
Visit our blog Like us on Facebook Follow us on Twitter View our videos on YouTube


Atlanta: Interesting Speakers Share Valuable Information

Last week, we hosted another MPN education program in Atlanta. Being in Atlanta was a bit nostalgic and heartwarming. Bonnie Evans, longtime partner and caregiver to Joe (now deceased), spoke about why she became involved on a grander scale in the MPN community. The Atlanta support group, founded by Bonnie, is still going strong. Marina Peed shared her experiences and journey as a patient and transplant survivor. Her unique challenges and ultimate cure led her to a new role as a strong advocate for MPN patients.  Dr. Jennifer Powers, a pharmacologist and MPN patient, imparted valuable information for those struggling with insurers and outlined the benefits of specialty pharmacies.   (Click here to read MPN Advocacy & Education International's Associate, Marina Peed's summary of Dr. Power's presentation.) 

Maria Hanik gave an informative overview of the BMT program at Northside Hospital Cancer Institute. Our clinicians and researchers, Drs. Rampal, Michaelis and Winton shared updates on current clinical trials, what MPNs look like and how the body reacts to polycythemia vera, essential thrombocythemia and myelofibrosis. The feedback we hear from patients after each educational program fuels our commitment to continue providing the best possible events and resources available.
Pictured above, top row, Dr. Michaelis, Dr. Powers, Ann Brazeau and Bonnie Evans, bottom row Dr. Rampal
MPN Horizons Meeting in Frankfurt, Germany 

The 2nd annual MPN Horizon's meeting took place in Frankfort recently.  Our ambassador and associate, Marina S. Peed, not only represented MPN Advocacy and Education International, but was asked to present. Marina blogged about her experience, click here to read more.
In the Trenches: 
Dr. Wendy Bernstein, MD  
Walter Reed Medical Center

Dr. Berstein, MD
Dr. Bernstein, MD, is a staff oncology and hematology physician and Chair of Scientific Review for the Department of Research Programs at Walter Reed National Military Medical Center. She is an Associate Professor of Medicine, and an adjunct Associate Professor of Pharmacology and of Microbiology at the Uniformed Services University of the Health Sciences (USUHS). Her research activities center on immune reconstitution and use of CAR-T cells in HIV infection. Dr. Bernstein is a 28-year veteran of the US Army Medical Corps, from where she retired with the rank of Colonel. She received her M.D. from USUHS and is Board certified in Internal Medicine, Hematology and Oncology.

Dr. Bernstein will be presenting at our MPN  Patient-Caregiver Program on November 10 in Washington, D.C.

The National Comprehensive Cancer Network  ( NCCN ) has released its latest addition to the NCCN  Guidelines for MPN Patients

The guidelines are intended to offer patients a comprehensive understanding of myeloproliferative neoplasms. It covers basic explanations of essential thrombocythemia, polycythemia vera and myelofibrosis as well as complicated decision-making related to the diagnosis, supportive care and available resources.
MPN Research Foundation's Progression Marker Project: Your Participation Can Make a Difference

"We need rigorous data to move physicians away from 'watch and wait' to treatment strategies based on an understanding 'why, how and when' people with MPNs should be treated. The Progression Marker Project is designed to provide us with this essential yet missing data."
Dr. Srdan
 Verstovsek, MD Anderson,  Principal Investigator

MPN Advocacy & Education International strongly supports this research project, which is a multi-year project that would collect samples and data from patients, using both their electronic medical records and their own self-reported experience with symptoms through the Foundation's patient registry. The one question patients ask us most often is "Will my MPN progress?" The great fear and anxiety of disease progression is very real. This timely and important project needs support from the entire MPN community. 
Clinical Trials
MPN Advocacy and Education International's website provides a comprehensive list of current clinical trials and research projects, as well as up-to-date news related to myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET).